Regeneron at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Regeneron brings 5 presentations to PEGS Europe 2026 in Lisbon. Its program centres on CD3-engaging bispecific antibodies for cancer, including how to move them into solid tumours and raise their anti-tumour activity through other T cell pathways. It also covers an approach to make gene delivery more tissue specific.

Organization	PEGS Europe 2026 Attendance
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company with marketed antibody medicines, discovered with its VelocImmune mice, and a pipeline including CD3 bispecifics.	Talk Tue Nov 17 11:15am–11:45am Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumour Activity of CD3-Engaging Bispecific Antibodies Safety and Efficacy of Bispecific and Multispecific Antibodies Chair Wed Nov 18 8:25am–8:30am Chairperson's Remarks Advancing Multispecific Antibodies and Combination Therapy to the Clinic Chair Wed Nov 18 2:00pm–2:05pm Chairperson's Remarks Advancing Multispecific Antibodies and Combination Therapy to the Clinic Talk Wed Nov 18 2:35pm–3:05pm A Novel Approach to Enhance Tissue Specific Gene Delivery Biologics for Autoimmune Diseases Talk Wed Nov 18 6:00pm–6:30pm Advancing CD3 Bispecifics for Solid Tumour Indications Engineering Antibodies & Beyond

Organization

PEGS Europe 2026 Attendance

Regeneron

Tarrytown, NY

regeneron.com

Large pharma

Biotechnology company with marketed antibody medicines, discovered with its VelocImmune mice, and a pipeline including CD3 bispecifics.

Talk

Tue Nov 17
11:15am–11:45am

Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumour Activity of CD3-Engaging Bispecific Antibodies

Safety and Efficacy of Bispecific and Multispecific Antibodies

Chair